Cervical Cancer Prevention Knowledge (Cckp-64) among Female Students in Novi Sad, Serbia during COVID-19 Pandemic
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Data Collection and Study Questionnaire
2.3. Statistical Analysis
3. Results
3.1. General Knowledge Regarding Cervical Cancer among Female Students at the University of Novi Sad
3.2. Relationship between Estimated Risk Factors and Occurrence of the Disease Cancer among Female Students of the University of Novi Sad
3.3. Knowledge about Primary Prevention of Cancer among Female Students of the University of Novi Sad
3.4. Knowledge about Secondary Prevention of Cancer among Female Students of the University of Novi Sad
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Escobar, N.; Plugge, E. Prevalence of human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer in imprisoned women worldwide: A systematic review and meta-analysis. J. Epidemiol. Community Health 2020, 74, 95–102. [Google Scholar] [CrossRef] [PubMed]
- Sherris, J.; Herdman, C.; Elias, C. Cervical cancer in the developing world. West. J. Med. 2001, 175, 231–233. [Google Scholar] [CrossRef] [PubMed]
- Memon, A.; Bannister, P. Epidemiology of Cervical Cancer. In Uterine Cervical Cancer; Farghaly, S., Ed.; Springer: Berlin/Heidelberg, Germany, 2019. [Google Scholar] [CrossRef]
- The Surveillance, Epidemiology, and End Results (SEER) Program. Available online: http://seer.cancer.gov (accessed on 21 January 2022).
- Saslow, D.; Solomon, D.; Lawson, H.W.; Killackey, M.; Kulasingam, S.L.; Cain, J.; Garcia, F.A.; Moriarty, A.T.; Waxman, A.G.; Wilbur, D.C.; et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 2012, 62, 147–172. [Google Scholar] [CrossRef] [PubMed]
- Lowy, D.R. HPV vaccination to prevent cervical cancer and other HPV-associated disease: From basic science to effective interventions. J. Clin. Investig. 2016, 126, 5–11. [Google Scholar] [CrossRef] [PubMed]
- Walker, T.Y.; Elam-Evans, L.D.; Yankey, D.; Markowitz, L.E.; Williams, C.L.; Fredua, B.; Singleton, J.A.; Stokley, S. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years—United States, 2018. MMWR Morb. Mortal. Wkly. Rep. 2019, 68, 718–723. [Google Scholar] [CrossRef] [PubMed]
- Kovačević, G.; Jovanović-Galović, A.; Petrović, V.; Vinarž, Ž.; Marinković, G.; Brašanac, B.; Milošević, V. Human papillomavirus infection prevalence in female university students in Novi Sad, Serbia. Srp. Arh. Celok. Lek. 2016, 144, 300–306. [Google Scholar] [CrossRef] [PubMed]
- Chidyaonga-Maseko, F.; Chirwa, M.L.; Muula, A.S. Underutilization of cervical cancer prevention services in low and middle income countries: A review of contributing factors. Pan Afr. Med. J. 2015, 21, 231. [Google Scholar] [CrossRef] [PubMed]
- Jovanovic, V.; Mitrovic Jovanovic, A.; Zivanovic, A.; Kocic, S.; Vasiljevic, M.; Krasic, V. Knowledge about cervical cancer, Pap test, and barriers to women’s participation in screening in Belgrade, Serbia. Eur. J. Gynaecol. Oncol. 2017, 38, 69–75. [Google Scholar] [PubMed]
- Webb, E.; Hernández-Quevedo, C.; Williams, G.; Scarpetti, G.; Reed, S.; Panteli, D. Providing health services effectively during the first wave of COVID-19: A cross-country comparison on planning services, managing cases, and maintaining essential services. Health Policy 2022, 126, 382–390. [Google Scholar] [CrossRef] [PubMed]
- Jaglarz, K.; Tomaszewski, K.A.; Kamzol, W.; Puskulluoglu, M.; Krzemieniecki, K. Creating and field-testing the questionnaire for the assessment of knowledge about cervical cancer and its prevention among schoolgirls and female students. J. Gynecol. Oncol. 2014, 25, 81–89. [Google Scholar] [CrossRef] [PubMed]
- Taber, K.S. The Use of Cronbach’s Alpha When Developing and Reporting Research Instruments in Science Education. Res. Sci. Educ. 2018, 48, 1273–1296. [Google Scholar] [CrossRef]
- Rančić, N.K.; Golubović, M.B.; Ilić, M.V.; Ignjatović, A.S.; Živadinović, R.M.; Đenić, S.N.; Momčilović, S.D.; Kocić, B.N.; Milošević, Z.G.; Otašević, S.A. Knowledge about Cervical Cancer and Awareness of Human Papillomavirus (HPV) and HPV Vaccine among Female Students from Serbia. Medicina 2020, 56, 406. [Google Scholar] [CrossRef] [PubMed]
- Kesic, V.; Markovic, M.; Matejic, B.; Topic, L. Awareness of cervical cancer screening among women in Serbia. Gynecol. Oncol. 2005, 99, 222–225. [Google Scholar] [CrossRef] [PubMed]
- Del Pilar Estevez-Diz, M.; Bonadio, R.C.; Miranda, V.C.; Carvalho, J.P. Management of cervical cancer patients during the COVID-19 pandemic: A challenge for developing countries. Ecancermedicalscience 2020, 14, 1060. [Google Scholar] [CrossRef] [PubMed]
- Sitaresmi, M.N.; Rozanti, N.M.; Simangunsong, L.B.; Wahab, A. Improvement of Parent’s awareness, knowledge, perception, and acceptability of human papillomavirus vaccination after a structured-educational intervention. BMC Public Health 2020, 20, 1836. [Google Scholar] [CrossRef] [PubMed]
- Marić, G.; Birčanin, Đ.; Kisić, V.; Dotlić, J.; Zarić, M.; Kisić, D.K.; Gazibara, T. Parental perspective on human papillomavirus (HPV) vaccination in Serbia: Knowledge, attitudes and practice. Sex. Reprod. Healthc. 2018, 16, 192–198. [Google Scholar] [CrossRef] [PubMed]
- Soliman, M.; Oredein, O.; Dass, C.R. Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil. Int. J. Mol. Cell. Med. 2021, 10, 101–113. [Google Scholar] [CrossRef] [PubMed]
- Kamolratanakul, S.; Pitisuttithum, P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines 2021, 9, 1413. [Google Scholar] [CrossRef] [PubMed]
- Tsui, J.; Martinez, B.; Shin, M.B.; Allee-Munoz, A.; Rodriguez, I.; Navarro, J.; Thomas-Barrios, K.R.; Kast, W.M.; Baezconde-Garbanati, L. Understanding medical mistrust and HPV vaccine hesitancy among multiethnic parents in Los Angeles. J. Behav. Med. 2022, 46, 100–115. [Google Scholar] [CrossRef] [PubMed]
- Dubé, E.; Gagnon, D.; MacDonald, N.E. Strategies intended to address vaccine hesitancy: Review of Published Reviews. Vaccine 2015, 33, 4191–4203. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Vaccine Safety Communication: Guide for Immunization Programme Managers and National Regulatory Authorities (1970). World Health Organization. Available online: https://apps.who.int/iris/handle/10665/208263 (accessed on 23 April 2023).
- World Health Organization. Immunization Coverage (No Date). World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage (accessed on 23 April 2023).
- Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”. Guidelines for Conduction of Obligatory and Recommended Active Immunization of the Population; Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”: Belgrade, Serbia, 2018. [Google Scholar]
Variable | Percentage | Frequency |
---|---|---|
Age | ||
17–19 | 14.7% | 59 |
20–22 | 39.3% | 158 |
23–25 | 29.6% | 119 |
>26 | 16.4% | 66 |
Field of study | ||
Natural sciences | 14.2% | 57 |
Technical sciences | 25.1% | 101 |
Humanistic sciences | 17.4% | 70 |
Social sciences | 22.9% | 92 |
Art sciences | 6.0% | 24 |
Other | 14.4% | 58 |
Living environment | ||
Rural environment | 6.2% | 25 |
Urban environment < 10,000 inhabitants | 23.1% | 93 |
Urban environment 10,000–100,000 inhabitants | 53.2% | 214 |
Urban environment > 100,000 inhabitants | 17.4% | 70 |
Questions | Yes | No | I Do Not Know |
---|---|---|---|
% (N) | % (N) | % (N) | |
Have you ever heard of cervical cancer? | 90.3 (363) | 9.5 (38) | 0.2 (1) |
Can cervical cancer be a terminal illness (or can you die from cervical cancer)? | 67.7 (272) | 3.5 (14) | 28.9 (116) |
Can cervical cancer be associated with an infection? | 49.3 (198) | 4.7 (19) | 46 (185) |
Is there an effective method that significantly reduces the risk of this disease? | 36.3 (146) | 28.9 (116) | 34.8 (140) |
Have you ever had direct contact with the disease (e.g., has any of your relatives or friends suffered from it)? | 9.7 (39) | 85.6 (344) | 4.7 (19) |
Do you think this disease could affect you in the future? | 25.4 (102) | 15.9 (64) | 58.7 (236) |
Factors | M | SD | Factor | M | SD |
---|---|---|---|---|---|
Young age | 0.96 | 1.320 | Miscarriages and abortions | 2.54 | 1.596 |
Genetic factor | 2.97 | 1.544 | A large number of pregnancies and childbirths | 2.38 | 1.620 |
HPV infection | 3.32 | 1.494 | Early menarche | 1.11 | 1.490 |
HIV infection | 3.21 | 1.444 | Use of condoms | 1.20 | 1.512 |
Multiple sexual partners | 3.48 | 1.507 | Hormonal contraception | 1.87 | 1.573 |
Early sexual initiation | 3.09 | 1.702 | Breast feeding | 1.25 | 1.462 |
History of STDs | 3.58 | 1.243 | Use of drugs or psychoactive substances | 2.12 | 1.629 |
Alcohol abuse | 2.05 | 1.585 | Using public swimming pools | 1.95 | 1.569 |
Smoking | 2.27 | 1.593 |
A. Lifestyle | B. Vaccine | ||||||
---|---|---|---|---|---|---|---|
Question | Yes | No | I Do Not Know | Question | Yes | No | I Do Not Know |
A diet rich in ‘so-called’ antioxidants? | 70.1% | 8.5% | 21.4% | Have you heard about the vaccine ‘against cervical cancer’? | 63.4% | 32.1% | 4.5% |
Regular physical exercise? | 78.6% | 11.4% | 10.0% | If such a vaccine exists, is it available in Serbia? | 52.0% | 6.7% | 41.3% |
Use of vitamin supplements? | 62.9% | 16.4% | 20.06% | Is it free of charge (reimbursed by the National Health Fund)? | 19.2% | 29.6% | 51.2% |
Proper, long and relaxing sleep? | 80.6% | 8.2% | 11.2% | Does it guarantee 100% protection from cervical cancer? | 4.2% | 54.2% | 41.5% |
Avoiding highly processed food? | 60.7% | 16.9% | 22.4% | Do you know where you can get vaccinated? | 31.8% | 28.9% | 39.3% |
Avoiding genetically modified food? | 67.2% | 11.4% | 21.4% | Have you ever been vaccinated? | 61.9% | 32.8% | 5.2% |
Weight loss? | 29.9% | 29.6% | 40.5% | ||||
Restraining from casual sex? | 60.7% | 16.4% | 22.9% | ||||
C. What is the best age (year) to get vaccinated? | 8 years | 20.1% | |||||
9–13 years | 24.9% | ||||||
14–18 years | 26.6% | ||||||
19–25 years | 21.1% | ||||||
>25 years | 7.2% |
Questions | Age Groups | χ2 | p | |||
---|---|---|---|---|---|---|
18–19 | 20–22 | 23–25 | >26 | |||
A diet rich in ‘so-called’ antioxidants? | 40 (67.8%) | 109 (69.0%) | 85 (71.4%) | 48 (72.7%) | 2.314 | 0.889 |
Regular physical exercise? | 49 (83.1%) | 126 (79.7%) | 89 (74.8%) | 52 (78.8%) | 8.069 | 0.233 |
Use of vitamin supplements? | 36 (61.0%) | 98 (62.0%) | 81 (68.1%) | 38 (57.6%) | 2.543 | 0.864 |
Proper, long and relaxing sleep? | 45 (76.3%) | 129 (81.6%) | 99 (83.2%) | 51 (77.3%) | 1.898 | 0.929 |
Avoiding highly processed food? | 37 (62.7%) | 96 (60.8%) | 67 (56.3%) | 44 (66.7%) | 3.634 | 0.726 |
Avoiding genetically modified food? | 38 (64.4%) | 106 (67.1%) | 74 (62.2%) | 52 (78.8%) | 7.545 | 0.273 |
Weight loss? | 17 (28.8%) | 45 (28.5%) | 40 (33.6%) | 18 (27.3%) | 5.949 | 0.429 |
Restraining casual sex? | 38 (64.4%) | 97 (61.4%) | 71 (59.7%) | 38 (57.9%) | 8.860 | 0.182 |
If such a vaccine exists, is it available in Serbia? | 24 (40.7%) | 69 (43.7%) | 76 (63.9%) | 40 (60.6%) | 23.203 | 0.001 * |
Is the vaccine safe? | 11 (18.6%) | 23 (14.6%) | 20 (16.8%) | 23 (34.8%) | 20.831 | 0.002 * |
Does it guarantee 100% protection from cervical cancer? | 32 (54.2%) | 78 (49.4%) | 73 (61.3%) | 35 (53.0%) | 8.103 | 0.231 |
What is the best age (year) to get vaccinated? | 10 (16.9%) | 37 (23.4%) | 25 (21.0%) | 28 (42.4%) | 34.670 | 0.001 * |
A. Distressing Symptoms—Select the Symptoms which May be Associated with the Presence of Cancer | B. Cytological Examination | ||||
---|---|---|---|---|---|
Question | Yes | No | Question | Yes | No |
Lack of symptoms from genital areas? | 25.9% | 74.1% | Have you ever heard about cytological examination? | 84.8% | 15.2% |
Painful menstruation | 32.3% | 67.7% | Is it a test that gives a 100% chance of early diagnosis of cervical cancer? | 36.8% | 63.2% |
Intensive periods or bleeding between periods? | 47.8% | 52.2% | Is the test painful? | 21.9% | 78.1% |
Irregular menstruation or lack of menstruation? | 40.8% | 59.2% | Is it a time-consuming test? | 5.2% | 94.8% |
Smelly vaginal discharge? | 45.5% | 54.5% | Is it possible to be tested free of charge? | 47.5% | 52.5% |
Blood-stained mucus? | 62.2% | 37.8% | Is it sufficient to do the test only once in order to eliminate the risk of cervical cancer? | 10.0% | 90.0% |
Itching in the genital area? | 32.8% | 67.2% | Can the test cause serious complications? | 5.7% | 94.3% |
Bleeding after intercourse? | 44.0% | 56.0% | Is it possible for the Pap smear to increase the susceptibility to cervical cancer in the future? | 4.7% | 95.3% |
High fever? | 40.8% | 59.2% | Do you think you should undergo cytological examination? | 60.0% | 40.0% |
At what age (year) can women in Serbia undergo cytological examination free of charge? | 17–25 years | 73.9% | |||
26–59 years | 11.2% | ||||
>60 years | 14.9% | ||||
How long (year) after sexual initiation should women undergo the test? | <1 years | 66.2% | |||
1–3 years | 32.8% | ||||
3–6 years | 0.5% | ||||
>6 years | 0.5% | ||||
How often (year) should women do the test? | Every year | 71.6% | |||
Every 3 years | 25.9% | ||||
Every 10 years | 2.2% | ||||
Only once | 0.2% |
Questions | Age Groups | χ2 | p | |||
---|---|---|---|---|---|---|
18–19 | 20–22 | 23–25 | >26 | |||
Lack of symptoms from genital areas? | 17 (28.8%) | 42 (26.6%) | 23 (19.3%) | 22 (33.3%) | 4.881 | 0.181 |
Painful menstruation | 18 (30.5%) | 60 (38.0%) | 34 (28.6%) | 18 (27.3%) | 3.930 | 0.269 |
Intensive periods or bleeding between periods? | 25 (42.4%) | 77 (48.4%) | 45 (37.8%) | 45 (68.2%) | 16.496 | 0.001 * |
Irregular menstruation or lack of menstruation? | 19 (32.2%) | 69 (43.7%) | 37 (31.1%) | 39 (59.1%) | 16.130 | 0.001 * |
Smelly vaginal discharge? | 20 (33.9%) | 74 (46.8%) | 44 (37.0%) | 45 (68.2%) | 20.495 | <0.001 * |
Blood-stained mucus? | 30 (50.8%) | 90 (57.0%) | 72 (60.5%) | 58 (87.9%) | 23.731 | <0.001 * |
Itching in the genital area? | 16 (27.1%) | 60 (38.0%) | 31 (26.1%) | 25 (37.9%) | 6.012 | 0.111 |
Bleeding intercourse? | 22 (37.3%) | 67 (42.4%) | 41 (34.5%) | 47 (71.2%) | 25.474 | <0.001 * |
High fever? | 13 (22.0%) | 71 (44.9%) | 40 (33.6%) | 40 (60.6%) | 22.986 | <0.001 * |
Is it a test that gives a 100% chance of early diagnosis of cervical cancer? | 42 (71.2%) | 107 (67.7%) | 78 (65.5%) | 27 (40.9%) | 17.386 | 0.001 * |
Is the test painful? | 42 (71.2%) | 132 (83.5%) | 90 (75.6%) | 50 (75.8%) | 5.025 | 0.170 |
Is the test painful? | 53 (89.8%) | 151 (95.6%) | 114 (95.8%) | 63 (95.5%) | 3.428 | 0.330 |
Is it possible to be tested free of charge? | 24 (40.7%) | 65 (41.1%) | 53 (44.5%) | 49 (74.2%) | 23.010 | <0.001 * |
Is it sufficient to do the test only once in order to eliminate the risk of cervical cancer? | 48 (81.4%) | 145 (91.8%) | 111 (93.3%) | 58 (87.9%) | 7.231 | 0.065 |
Can the test cause serious complications? | 58 (98.3%) | 148 (93.7%) | 110 (92.4%) | 63 (95.5%) | 2.799 | 0.424 |
Is it possible for the Pap smear to increase the susceptibility to cervical cancer in the future? | 58 (98.3%) | 152 (96.2%) | 110 (92.4%) | 63 (95.5%) | 3.638 | 0.303 |
How long (year) after sexual initiation should women undergo the test? | 32 (54.2%) | 103 (65.2%) | 78 (65.5%) | 53 (80.3%) | 14.991 | 0.091 |
How often (year) should women do the test? | 31 (52.5%) | 108 (68.4%) | 87 (73.1%) | 62 (93.9%) | 35.851 | <0.001 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tomić, S.D.; Ćorić, A.; Tomić, S.; Mujičić, E.; Malenković, J.; Šljivo, A.; Malenković, G. Cervical Cancer Prevention Knowledge (Cckp-64) among Female Students in Novi Sad, Serbia during COVID-19 Pandemic. Healthcare 2023, 11, 1400. https://doi.org/10.3390/healthcare11101400
Tomić SD, Ćorić A, Tomić S, Mujičić E, Malenković J, Šljivo A, Malenković G. Cervical Cancer Prevention Knowledge (Cckp-64) among Female Students in Novi Sad, Serbia during COVID-19 Pandemic. Healthcare. 2023; 11(10):1400. https://doi.org/10.3390/healthcare11101400
Chicago/Turabian StyleTomić, Sanja D, Andrijana Ćorić, Slobodan Tomić, Ermina Mujičić, Jelena Malenković, Armin Šljivo, and Goran Malenković. 2023. "Cervical Cancer Prevention Knowledge (Cckp-64) among Female Students in Novi Sad, Serbia during COVID-19 Pandemic" Healthcare 11, no. 10: 1400. https://doi.org/10.3390/healthcare11101400
APA StyleTomić, S. D., Ćorić, A., Tomić, S., Mujičić, E., Malenković, J., Šljivo, A., & Malenković, G. (2023). Cervical Cancer Prevention Knowledge (Cckp-64) among Female Students in Novi Sad, Serbia during COVID-19 Pandemic. Healthcare, 11(10), 1400. https://doi.org/10.3390/healthcare11101400